financetom
Business
financetom
/
Business
/
Darden Restaurants' Fiscal Q3 Adjusted Earnings, Sales Rise; Fiscal 2024 Outlook Updated, $1 Billion Buyback Plan Approved
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Darden Restaurants' Fiscal Q3 Adjusted Earnings, Sales Rise; Fiscal 2024 Outlook Updated, $1 Billion Buyback Plan Approved
Mar 21, 2024 4:52 AM

07:25 AM EDT, 03/21/2024 (MT Newswires) -- Darden Restaurants ( DRI ) reported fiscal Q3 adjusted net earnings from continuing operations Thursday of $2.62 per diluted share, up from $2.34 a year earlier.

Analysts polled by Capital IQ expected $2.62.

Sales for the quarter ended Feb. 25 was $2.97 billion, up from $2.79 billion a year earlier.

Analysts surveyed by Capital IQ expected $3.03 billion.

The restaurant chain operator said it now expects fiscal 2024 adjusted earnings from continuing operations of $8.80 to $8.90 per diluted share, compared with its previous guidance of $8.75 to $8.90. Analysts polled by Capital IQ expect $8.86.

Total sales for the fiscal year are now expected at $11.4 billion, down from its earlier outlook of $11.5 billion. Analysts polled by Capital IQ expect $11.57 billion. Analysts surveyed by Capital IQ expect $11.46 billion.

Darden maintained its quarterly dividend at $1.31 per share, payable May 1 to shareholders of record as of April 10.

The company said its board approved a new $1 billion share buyback plan, which replaces its existing plan and has no expiration date.

Shares of Darden were down more than 4% in recent Thursday premarket activity.

Price: 166.52, Change: -8.06, Percent Change: -4.62

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ISS' Guerra to leave proxy advisory firm and join Strategic Governance Advisors
ISS' Guerra to leave proxy advisory firm and join Strategic Governance Advisors
Jan 21, 2025
NEW YORK (Reuters) - Cristiano Guerra, who has been instrumental in determining the outcome of some of the America's most hotly contested board battles as head of special situations research at Institutional Shareholder Services, is leaving the proxy advisory firm, sources familiar with the move told Reuters. Guerra will join Strategic Governance Advisors, a unit of strategic advisory and communications...
Mercury Systems Says it was Awarded a $24.5 Million Data Processing US Defense Department Satellite Program Contract
Mercury Systems Says it was Awarded a $24.5 Million Data Processing US Defense Department Satellite Program Contract
Jan 21, 2025
09:58 AM EST, 01/21/2025 (MT Newswires) -- Mercury Systems ( MRCY ) said Tuesday it has been awarded a $24.5 million contract with a space systems contractor to develop a data processing and storage subsystem for a satellite program of the US Defense Department. The company said it will deliver a number of subsystems under the contract using its products...
Critical Metals to Launch Bitcoin Treasury Strategy
Critical Metals to Launch Bitcoin Treasury Strategy
Jan 21, 2025
09:47 AM EST, 01/21/2025 (MT Newswires) -- Critical Metals (CRML) said Tuesday it will adopt bitcoin as a primary asset in its treasury program. The company said that, under a convertible note deal led by JBA Asset Management, it may have access to up to $500 million to buy bitcoin, with $100 million closing in the first tranche. The first...
KalVista Says Japan Health Ministry Grants Orphan Drug Designation to Sebetralstat
KalVista Says Japan Health Ministry Grants Orphan Drug Designation to Sebetralstat
Jan 21, 2025
09:51 AM EST, 01/21/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Tuesday that Japan's Ministry of Health, Labour and Welfare granted Orphan Drug Designation for sebetralstat and accepted its New Drug Application for the treatment of hereditary angioedema. The company said the application is based on results from a late-stage trial that evaluated the safety and efficacy of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved